Neumora Therapeutics
NMRA
102 hedge funds and large institutions have $113M invested in Neumora Therapeutics in 2025 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 22 reducing their positions, and 12 closing their positions.
5,635% more call options, than puts
Call options by funds: $1.32M | Put options by funds: $23K
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
50% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 22
22% more capital invested
Capital invested by funds: $92.2M → $113M (+$20.4M)
10% more funds holding
Funds holding: 93 → 102 (+9)
6.37% more ownership
Funds ownership: 31.3% → 37.67% (+6.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.04M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$4.23M |
| 3 |
Millennium Management
New York
|
+$3.52M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.77M |
| 5 |
Two Sigma Investments
New York
|
+$2.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$3.53M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$948K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$780K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$249K |
| 5 |
SoftBank Group
Tokyo,
Japan
|
-$244K |
NMRA Hedge Fund Activity: Q4 2025 in Review
102 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q4 2025, worth a combined $113M — up 22% from $92.2M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new NMRA positions and 12 closed out — a net gain of 12 holders — while 33 added to existing stakes and 22 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $8.04M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $3.53M sold.
- 102 institutional investors held Neumora Therapeutics (NMRA) as of Q4 2025, up from 93 in Q3 2025.
- Funds reported $113M of Neumora Therapeutics stock for Q4 2025, up 22% quarter-over-quarter.
- 24 funds opened new Neumora Therapeutics positions in Q4 2025 and 12 closed out, a net change of +12 holders.
- The largest Neumora Therapeutics buyer in Q4 2025 was Point72 Asset Management, an estimated $8.04M added.
- The largest Neumora Therapeutics seller in Q4 2025 was T. Rowe Price Investment Management, an estimated $3.53M sold.
Based on aggregated 13F filings for Q4 2025.